Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline.

Awan, Ahmed Arslan Yousuf;Berenguer, Marina C;Bruchfeld, Annette;Fabrizi, Fabrizio;Jadoul, Michel;et.al.
(2023) Annals of Internal Medicine — Vol. 176, n° 12, p. 1648-1655 (2023)

Files

Awan-et-al-2023-prevention-diagnosis-evaluation-and-treatment-of-hepatitis-c-in-chronic-kidney-disease-synopsis-of-the-KDIGO20.pdf
  • Open Access
  • Adobe PDF
  • 337.61 KB
Download

Details

Authors
  • Awan, Ahmed Arslan Yousuf
    Author
  • Berenguer, Marina Corcid-logo
    Author
  • Bruchfeld, Annetteorcid-logo
    Author
  • Fabrizi, Fabrizio
    Author
  • Jadoul, Michelorcid-logoUCLouvain
    Author
Show more
Abstract
(en) DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 clinical practice guideline on prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease (CKD) is an update of the 2018 guideline from KDIGO. METHODS: The KDIGO Work Group (WG) updated the guideline, which included reviewing and grading new evidence that was identified and summarized. As in the previous guideline, the WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and used expert judgment to develop recommendations. New evidence led to updating of recommendations in the chapters on treatment of hepatitis C virus (HCV) infection in patients with CKD (Chapter 2), management of HCV infection before and after kidney transplant (Chapter 4), and diagnosis and management of kidney disease associated with HCV infection (Chapter 5). Recommendations in chapters on detection and evaluation of hepatitis C in CKD (Chapter 1) and prevention of HCV transmission in hemodialysis units (Chapter 3) were not updated because of an absence of significant new evidence. RECOMMENDATIONS: The 2022 updated guideline includes 43 graded recommendations and 20 ungraded recommendations, 7 of which are new or modified on the basis of the most recent evidence and consensus among the WG members. The updated guidelines recommend expanding treatment of hepatitis C with sofosbuvir-based regimens to patients with CKD glomerular filtration rate categories G4 and G5, including those receiving dialysis; expanding the donor pool for kidney transplant recipients by accepting HCV-positive kidneys regardless of the recipient's HCV status; and initiating direct-acting antiviral treatment of HCV-infected patients with clinical evidence of glomerulonephritis without requiring kidney biopsy. The update also addresses the use of immunosuppressive regimens in such patients.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Awan, A. A. Y., Berenguer, M. C., Bruchfeld, A., Fabrizi, F., Goldberg, D. S., Jia, J., Kamar, N., Mohamed, R., Pessôa, M. G., Pol, S., Sise, M. E., Balk, E. M., Gordon, C. E., Adam, G., Cheung, M., Earley, A., Martin, P., & Jadoul, M. (2023). Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline. Annals of Internal Medicine, 176(12), 1648-1655. https://doi.org/10.7326/M23-2391 (Original work published 2023)